We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
-11.09%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.96B
AUM Growth
-$1.12B
Cap. Flow
-$341M
Cap. Flow %
-11.5%
Top 10 Hldgs %
72.49%
Holding
61
New
8
Increased
6
Reduced
4
Closed
10

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$239M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$205M
3
MRSN
Mersana Therapeutics
MRSN
+$36.8M
4
ARVN icon
Arvinas
ARVN
+$35.6M
5
SLRN
ACELYRIN
SLRN
+$29.8M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$419M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$124M
3
BPMC
Blueprint Medicines
BPMC
+$114M
4
RVMD icon
Revolution Medicines
RVMD
+$48.1M
5
DYN icon
Dyne Therapeutics
DYN
+$8.99M

Sector Composition

Rank Sector Weight
1 Healthcare 98.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LENZ
26
LENZ Therapeutics
LENZ
$179M
$21.2M 0.71%
1,219,778
– –
AVIR icon
27
Atea Pharmaceuticals
AVIR
$386M
$21M 0.71%
6,995,861
– –
ORIC icon
28
Oric Pharmaceuticals
ORIC
$1.24B
$20.7M 0.7%
3,418,068
– –
EWTX icon
29
Edgewise Therapeutics
EWTX
$4.48B
$20M 0.68%
3,493,194
– –
THRD
30
DELISTED
Third Harmonic Bio
THRD
$19.1M 0.64%
2,982,444
+893,664
+43% +$5.46M
SLRN
31
DELISTED
ACELYRIN
SLRN
$14.3M 0.48%
+1,402,201
New +$29.8M
ALLO icon
32
Allogene Therapeutics
ALLO
$604M
$14.2M 0.48%
4,488,200
– –
TCRX icon
33
TScan Therapeutics
TCRX
$50.2M
$12.8M 0.43%
5,000,000
– –
DCPH
34
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$12.6M 0.43%
+993,000
New +$13.7M
GBIO
35
DELISTED
Generation Bio
GBIO
$7.76M 0.26%
204,687
– –
GOSS icon
36
Gossamer Bio
GOSS
$97.5M
$7.66M 0.26%
+9,195,404
New +$10.6M
PHAT icon
37
Phathom Pharmaceuticals
PHAT
$953M
$7.26M 0.24%
700,000
– –
NGM
38
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$6.89M 0.23%
6,435,518
– –
PRME icon
39
Prime Medicine
PRME
$544M
$5.72M 0.19%
600,000
– –
PRQR icon
40
ProQR Therapeutics
PRQR
$244M
$3.87M 0.13%
2,980,016
– –
PRLD icon
41
Prelude Therapeutics
PRLD
$310M
$3.58M 0.12%
1,157,452
– –
ALGS icon
42
Aligos Therapeutics
ALGS
$25.2M
$2.95M 0.1%
157,934
– –
HOOK
43
DELISTED
HOOKIPA Pharma
HOOK
$2.83M 0.1%
459,502
– –
SYRE icon
44
Spyre Therapeutics
SYRE
$8.69B
$2.45M 0.08%
199,996
-4
-0% -$53
ALLK
45
DELISTED
Allakos
ALLK
$1.7M 0.06%
748,900
– –
NUVB.WS
46
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$1.29M 0.04%
963,333
– –
RVMD icon
47
CALL
Revolution Medicines
RVMD
$40B
$866K 0.03%
+31,300
New +$928K
NAMSW icon
48
NewAmsterdam Pharma Warrant
NAMSW
$87.4M
$617K 0.02%
66,665
– –
TPST icon
49
Tempest Therapeutics
TPST
$14.9M
$284K 0.01%
71,615
-14,803
-17% -$142K
CMAXW
50
DELISTED
CareMax, Inc. Warrant
CMAXW
$212K 0.01%
100,000
– –
1
2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q3 2023 Portfolio in Review

As of Q3 2023, EcoR1 Capital held 61 positions worth $2.96B, down 27% from $4.08B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

EcoR1 Capital withdrew a net $341M in Q3 2023, closing 10 positions and reducing 4 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $419M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 93% a quarter earlier.

Against the trend, EcoR1 Capital opened a new position in Mirati Therapeutics, Inc. Common Stock worth $250M.

  • EcoR1 Capital's largest Q3 2023 buy was Mirati Therapeutics, Inc. Common Stock: 5,748,399 shares worth $250M.
  • EcoR1 Capital added most to Apellis Pharmaceuticals in Q3 2023, an estimated $239M increase.
  • EcoR1 Capital's biggest Q3 2023 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $124M.
  • EcoR1 Capital fully exited Sarepta Therapeutics in Q3 2023, selling an estimated $419M.
  • EcoR1 Capital's ten largest holdings make up 72% of its $2.96B portfolio in Q3 2023.
  • EcoR1 Capital opened 8 new positions and closed 10 in Q3 2023.
  • EcoR1 Capital's portfolio value fell 27% quarter-over-quarter to $2.96B.

Based on EcoR1 Capital's 13F filing for Q3 2023, filed 14 Nov 2023.